Table 1.
Participant demographics, characteristics, and clinical measures at baseline.
| Characteristic | Control | Exercise | Total | Control vs. Exercise p-valuea |
|---|---|---|---|---|
| Total participants | 170 | 173 | 343 | |
| Female sex | 161 (95%) | 159 (92%) | 320 (93%) | 0.298 |
| Age, years (mean ± std. dev) | 55.6 ± 11.8 | 56.3 ± 12.9 | 55.9 ± 12.4 | 0.655 |
| Body mass index, kg/m2 (mean ± std. dev.) | 29.9 ± 6.5 | 30.6 ± 7.0 | 30.3 ± 6.7 | 0.090 |
| Obese (body mass index > 30 kg/m2) | 68 (40%) | 85 (49%) | 153 (45%) | 0.103 |
| Race | 0.712 | |||
| White | 143 (84%) | 148 (86%) | 291 (85%) | |
| Non-White | 27 (16%) | 25 (14%) | 52 (15%) | |
| Employment | 0.555 | |||
| Employed outside the house | 105 (62%) | 98 (57%) | 203 (59%) | |
| Self-employed / homemaker | 18 (11%) | 18 (10%) | 36 (10%) | |
| Unemployed | 47 (28%) | 57 (33%) | 104 (30%) | |
| Marital status | 0.107 | |||
| Married or long-term committed relationship | 108 (64%) | 124 (72%) | 232 (68%) | |
| Divorced, separated, single, widowed | 62 (36%) | 49 (28%) | 111 (32%) | |
| Education | 0.623 | |||
| At least some college | 117 (69%) | 118 (68%) | 235 (69%) | |
| High school/GED degree | 44 (26%) | 49 (28%) | 93 (27%) | |
| No high school or GED degree | 8 (5%) | 5 (3%) | 13 (4%) | |
| Cancer typeb | 0.272 | |||
| Breast | 136 (80%) | 131 (76%) | 267 (78%) | |
| Lymphoma | 3 (2%) | 8 (5%) | 11 (3%) | |
| Colon | 7 (4%) | 14 (8%) | 21 (6%) | |
| Lung | 2 (1%) | 1 (1%) | 3 (1%) | |
| Other | 9 (5%) | 8 (5%) | 17 (5%) | |
| Cancer stage | 0.843 | |||
| Stage I | 44 (26%) | 44 (25%) | 88 (26%) | |
| Stage II | 78 (46%) | 75 (43%) | 153 (45%) | |
| Stage III | 44 (26%) | 47 (27%) | 91 (27%) | |
| Stage IV | 2 (1%) | 4 (2 %) | 6 (2%) | |
| Not reported | 2 (1%) | 3 (2%) | 5 (1%) | |
| Chemotherapy type | 0.565 | |||
| Cyclophosphamide + doxorubicin | 66 (39%) | 62 (36%) | 128 (37%) | |
| Cyclophosphamide + docetaxel/paclitaxel | 60 (35%) | 50 (29%) | 110 (32%) | |
| Carboplatin + docetaxel/paclitaxel | 20 (12%) | 22 (13%) | 42 (12%) | |
| FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) | 7 (4%) | 7 (4%) | 14 (4%) | |
| Otherc | 4 (2%) | 10 (6%) | 14 (4%) | |
| CMF (cyclophosphamide, methotrexate, fluorouracil) | 4 (2%) | 8 (5%) | 12 (3%) | |
| Carboplatin/cisplatin/oxaliplatin | 5 (3%) | 6 (3%) | 11 (3%) | |
| R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) | 2 (1%) | 5 (3%) | 7 (2%) | |
| Unspecified | 2 (1%) | 3 (2%) | 5 (1%) | |
| Previous treatment | 0.464 | |||
| Previous surgery | 148 (87%) | 155 (90%) | 303 (88%) | |
| Previous radiation therapy | 1 (1%) | 5 (3%) | 6 (2%) | |
| Previous hormone therapy | 6 (4%) | 9 (5%) | 15 (4%) | |
| Time since previous treatment | ||||
| Weeks since end of first surgery for cancer (mean ± std. dev) | 4.5 ± 4.3 | 5.0 ± 6.4 | ± | 0.426 |
| Weeks since end of first radiation for cancer (mean ± std. dev) | 3 ± NA | 5 ± 470.6 | NA | |
| Weeks since end of first hormone therapy for cancer (mean ± std. dev) | 11 ± 19.1 | 71.8 ± 169.7 | 0.318 | |
| Karnofsky performance status (mean ± std. dev) | 94.8 ± 6.7 | 94.5 ± 7.0 | 94.6 ± 6.9 | 0.616 |
a
Statistical tests includes t-test or χ2 test
b
Other cancer types include endometrial, ovary, testes, uterine, brain, cervical, fallopian tube, head or neck, kidney, pancreas, and peritoneum.
GED, general educational development
c
Other chemotherapy types include combinations of cyclophosphamide, epirubicin, bendamustine, rituximab, bleomycin, doxorubicin, vinblastine, vincristine, irinotecan, 5-fluorouracil, and lenalidomide